*To the Editor*:

We read with keen interest the results of a randomized controlled trial of the Spiration Valve System in patients with severe emphysema by Criner and colleagues ([@bib1]). We congratulate the authors for presenting a well-designed study on an important clinical question. It has been previously reported that use of endobronchial valves in severe emphysema leads to improvement in FEV~1~ compared with placebo, similar to the results found in the present study ([@bib2]). However, some important points regarding the reported results need careful consideration and further discussion.

Although the authors report significant improvement in FEV~1~ compared with baseline on 6-month follow-up in the valve group, the overall responder rate is only 37%; that is, only approximately one-third of all patients who received the valve actually demonstrated benefit in airflow. Similarly, although the patient-centered outcomes (i.e., dyspnea and quality of life) improved in the valve group, they did so in only 53% and 54% of subjects, respectively, at 6 months. We feel that this response rate is extremely low by any standard, especially considering the high cost and potential complications associated with valve placement. Therefore, it would be desirable to interpret these results in the proper perspective, based on cost benefit.

Considering the patient population in which endobronchial valve therapy is being considered (i.e., those with severe airflow limitation, limited exercise capacity, and receiving long-term oxygen therapy), it may be worthwhile to identify predictors of nonresponse in the endobronchial valve therapy group in an attempt to identify patients most likely to derive benefit from this intervention. This may have important implications for rationalizing clinical practice of emphysema management.
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